

# Measles Outbreak in Complex Emergency: Estimating Vaccine Effectiveness and Evaluation of the Vaccination Campaign in Borno State, Nigeria, 2019

**Anne Eudes Jean Baptiste** (✉ [jeana@who.int](mailto:jeana@who.int))

World Health Organization Country Office for Nigeria <https://orcid.org/0000-0003-3240-7406>

**John Wagai**

World Health Organization Country Office for Nigeria

**Richard Ray Luce Jr**

World Health Organization Inter-country Support Team for West Africa

**Balcha Girma Masresha**

World Health Organization African Regional Office

**Don Klinkenberg**

Institute of Public Health and The Environment

**Irene Veldhuijzen**

Institut of Public Health and The Environment

**Joseph Oteri**

National Primary Health Care Development Agency

**Boubacar Dieng**

Technical Assisstance GAVI Alliance

**Obianuju Caroline Ikeonu**

World Health Organization Country Office for Nigeria

**Sule Mele**

State Primary Health Care Development Agency

**Musa Idowu Audu**

World Health Organization Country Office for Nigeria

**Fiona Braka**

World Health Organization Country Office for Nigeria

**Susan Hahné**

Institute of Public Health and The Environment

**Lieke E.A.M. Sanders**

Institute of Public Health and The Environment

**Eelko Hak**

University of Groningen

---

## Research article

**Keywords:** Measles, Coverage, Effectiveness, Emergency, Nigeria

**Posted Date:** January 20th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-34385/v3>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published on March 4th, 2021. See the published version at <https://doi.org/10.1186/s12889-021-10436-1>.

## Abstract

**Background:** From January to May 2019, large measles outbreaks affected Nigeria. Borno state was the most affected, recording 15,237 suspected cases with the state capital of Maiduguri having 1,125 cases investigated and line-listed by March 2019. In Borno state, 22 of the 27 Local Government Areas (LGAs or Districts), including 37 internally displaced persons (IDPs) camps were affected. In response to the situation, an outbreak response immunization (ORI) campaign was conducted in the 13 most affected LGAs. In addition to conventional vaccination teams, special teams were deployed in security compromised areas, areas with migrants, and for nomadic and IDPs. Here we describe the outbreak and the ORI campaign. We also assess the measles-containing vaccine (MCV) coverage and vaccine effectiveness (VE) in order to quantify the population-level impact

**Methods:** We reviewed the ORI activities, and conducted an analysis of the surveillance and the outbreak investigation reports. We assessed VE of MCV by applying the screening-method. Sensitivity analyses were also conducted to assess the effect of final classification of cases on the VE of MCV. The MCV coverage was assessed by a post-campaign coverage survey (PCCS) after completion of the ORI through a quantitative survey in the 12 LGAs that were accessible.

**Results:** Of the total 15,237 reported measles cases, 2,002 cases were line-listed and investigated, and 737 were confirmed for measles by week 9 of 2019. Of the investigated cases 67.3% (n = 1,348) were between 9 and 59 months of age. Among the 737 confirmed cases, only 9% (n = 64) stated being vaccinated with at least 1 dose of MCV. The overall VE for MCV was 98.4 % (95%CI: 97.8 – 98.8). No significant differences were observed in the VE estimates of lab-confirmed and epi-linked cases when compared to the original estimates. The aggregated weighted vaccination coverage was 85.7% (95% CI: 79.6 – 90.1).

**Conclusion:** The experience in Borno demonstrates that adequate VE can be obtained in conflict-affected areas. In complex emergencies affected by measles outbreaks, health authorities may consider integration with other health strategies and the engagement of security personnel as part of the ORI activities.

## Background

Between 2017 and early 2019, a global resurgence in measles cases and outbreaks has been observed [1,2]. Four of the six World Health Organization (WHO) geographic regions reported significant increases in the number and size of measles outbreaks. The most affected countries were Madagascar, Ukraine, Philippines and Nigeria. Reported outbreaks worldwide have been attributed to areas of persistently low measles vaccination coverage [1,2].

Nigeria has experienced repeated outbreaks of measles in recent years due to low routine immunization (RI) coverage. The country introduced measles vaccination into the RI program in 1978 for children aged 9 months. As at 2005, the national level administrative coverage was 32% [3]. Data from the 2018 Demographic and Health Survey (DHS) indicated that only 54% of children 12 – 23 months had received measles vaccine [4]; far below the herd protection threshold [5]. From January to May 2019, large measles outbreaks affected all 36 states in Nigeria and the Federal Capital Territory (FCT). By the beginning of May 2019, there were more than 28,000 suspected measles cases reported and 89 associated deaths with measles. A majority of cases were reported in Borno State with over 15,000 suspected cases and 75 measles deaths across 37 internally displaced persons (IDP) camps in 22 Local Government Areas (LGAs or Districts). High measles-associated mortality rates have been previously reported from IDP camps, and measles has been one of the major causes of child deaths in humanitarian emergencies [6,7].

To respond to measles outbreaks in emergencies, the WHO recommends a range of epidemic control activities. These include review of epidemiological and immunization program data to identify the cause (s) of the outbreak, intensive measles surveillance, improving coverage amongst high risk populations and implementing supplementary immunization activities (SIA) in areas not yet affected by the outbreak [8]. In addition, complex humanitarian emergencies pose considerable logistical challenges to the delivery of vaccination services including maintaining appropriate cold chain conditions for vaccine storage. High vaccine effectiveness (VE) is critical to halt outbreaks and prevent ongoing transmission during complex emergencies. Thus, estimating the VE of measles-containing vaccine (MCV) following a large measles outbreak is an essential part of assessing the quality and efficacy of the response [9,10].

During the 2019 measles outbreak in Borno state, the government of Nigeria through its National Primary Health Care Development Agency (NPHCDA), conducted two phases (March and May) of measles outbreak response immunization (ORI) in the most affected areas of the state. Here we describe the outbreak response and its impact in Borno State by assessing the investigated and confirmed measles cases as well as their vaccination status. To assess the population-level impact, we estimated the age-specific VE for MCV by applying the screening method on these data, and by estimating the vaccination coverage using a post-campaign coverage survey (PCCS).

## Methods

### *Setting*

Borno State is located in North East of Nigeria with a land mass of 75,481 square kilometer and a population of about 6.4 million people (2019 population census projections) [11]. The state shares an international boundary with Niger Republic, Chad and Cameroon. It shares interstate borders with Yobe (to the West), Adamawa (to the South), and Gombe (to the South West). Borno has 27 LGAs comprising a total of 311 political wards, out of which 201 are accessible for immunization and surveillance activities, and were fully accessible at the time of the ORI. The 2018 DHS indicated that 46.5% of children aged 12-23 months were vaccinated with MCV in Borno [4].

Since 2009, an armed insurgency has been ongoing in Borno State. This has resulted in the displacement of communities and the disruption of health services due to destruction of health facilities and out-migration of health personnel. The last weeks of December 2018 witnessed increased attacks on civilian populations by armed groups and resulted in a massive population displacement from security-compromised areas, including inaccessible settlements (communities), into the metropolitan LGAs of the state. By January 2019, more than 700,000 people were living in overcrowded camp-like settings, significantly increasing the risk of epidemics and infectious diseases. As a result, approximately 20% of the population of Borno State are living in IDPs camps in hosted communities [12].

### *Case reporting and definition of outbreak and cases*

In Nigeria, measles case-based surveillance is integrated with the polio acute flaccid paralysis surveillance structure and includes four national measles serological laboratories capable of testing on specimens from suspected measles cases for immunoglobulin (Ig) M antibodies as described elsewhere [13]. The surveillance performance is monitored regularly using performance monitoring indicators (i.e. proportion of LGAs with at least 1 suspected measles case reported with a blood specimen in a year, proportion of reported suspected cases from whom blood specimen is collected, non-measles febrile rash illness rate, and incidence of confirmed measles per million population). The measles surveillance system is sufficiently sensitive to identify and confirm measles cases. With one exception (i.e. incidence of confirmed measles per million population), the annual targets for the core measles surveillance performance indicators have been met since 2017 [14]. In brief, the surveillance network runs from the settlements and wards through the LGAs and States to the National level. The network consists of disease surveillance and notification officers (DSNOs) in all the LGAs in the country with State Epidemiologists at the State level. It is therefore institution-based and consists of formal and informal healthcare delivery points (reporting sites) and non-formal health care providers (informants). Additional to the installed surveillance network, a community-based surveillance makes use of community informants (i.e. traditional birth attendants, patent drug vendors, traditional healers) to report suspected cases.

A measles outbreak was defined as the occurrence of three or more confirmed measles cases in a unit (i.e. health facility/LGA/community with an approximate catchment population of  $\geq 100,000$ ) in a month [15][8]. We reviewed measles outbreak investigation reports and measles cases line-listed by the DSNO, WHO Borno State office and the rapid response team (RRT) deployed to Borno. Data collected included name, address (i.e. rural vs urban, LGA, ward, settlement/community), age, sex, date of rash onset, vaccination status, date of last vaccination, date of specimen collection and, final classification of cases as at epidemiologic week 9. Additional data was collected from the measles case based surveillance database regarding date of rash onset, age, vaccination status, lab-confirmed – positive serologic test for measles IgM antibody, epidemiologic linkage, and clinically compatible cases. WHO case definitions for measles were used for final classification of cases [16].

### *Measles Outbreak Response Immunization – ORI*

To improve population immunity and interrupt the large measles outbreak, the ORI was conducted in 2 phases. An objective of the ORI was to reach the underserved children aged between 6 months and 71 months. Key elements considered by NPHCDA to determine the target population and scope of the vaccination activities included routine vaccination coverage, age-specific of lab-confirmed cases, absolute number of cases (suspected and lab-confirmed) and, results of the measles risk assessment. Phase 1 targeted children in 8 wards of the state capital of Maiduguri Metropolitan Council (MMC) from the 21<sup>st</sup> to the 25<sup>th</sup> of March 2019.

Phase 2 was implemented from the 14<sup>th</sup> to the 21<sup>st</sup> of May 2019, and included accessible wards of 13 LGAs out of the 27 LGAs of Borno States. In addition to conventional vaccination teams, special teams were used during the response. These teams, with the support of local vigilante and military, were deployed during the 2<sup>nd</sup> phase of the campaign to safely operate in security compromised areas, areas with migrant and other special populations (i.e. nomadic, IDPs in camps and those embedded host community). The processes of engagement of security personnel to access security-compromised areas was described elsewhere [17]. A total of 37 special teams were used to reach underserved children in partially accessible and/or security compromised areas of the LGA.

#### *Estimation of measles vaccine effectiveness (VE)*

Measles VE was calculated using the screening method according to the following formula:  $VE = 1 - ((PCV / (1 - PCV)) * (1 - PPV) / PPV)$ ; where PCV is the proportion of cases vaccinated and PPV is the proportion of the population vaccinated. The screening method estimates VE by comparing vaccination coverage in cases of a disease (PCV) with the vaccination coverage in the population from which the cases are derived (PPV). PCV was calculated from the outbreak investigation reports and the measles surveillance database, and PPV was computed from the 2018 PCCS report. Evaluation of VE was assessed in children 9 months to 71 months of age for a more accurate estimate of the VE. Infants below the age of 9 months were not scheduled for measles vaccination and were excluded from the VE estimation. Likewise, cases reported from IDP camps were excluded from the VE estimation as the PCCS did not capture coverage from IDP camps.

#### *Sensitivity Analysis*

We conducted a sensitivity analysis where we compared the VE for lab-confirmed cases with the VE for epi-linked cases. As the original VE calculation, we did not consider cases reported from IDP camps nor vaccination of under 9 months. The sensitivity analysis was performed to assess the effect of final classification of cases on the MCV VE estimate.

#### *PCCS – Sample design*

We designed a quantitative survey assessment of the ORI after completion of the 2<sup>nd</sup> phase of the ORI. The survey was a two-stage cluster household survey. A unique sample design was applied in the Borno PCCS. Due to absence of a recent sampling frame and limited funds to conduct household listing, the aggregate of ward micro-plans, which contained the number of settlements in a ward and the estimated population per settlement, was used as the sampling frame for this survey. The settlement was randomly selected as the primary sampling unit and individual households as secondary sampling units. The primary sampling frame consisted of 1,044 settlements from which 120 primary sampling units (settlements) were selected in the 12 accessible LGAs at the time of the survey. The secondary sampling involved the selection of households within each settlement by using systematic random sampling. All the households in a settlement were visited, and eligible households with children aged 9 months to 71 months identified and line listed formed the settlement sampling frame. We calculated the sampling interval by dividing the total number of eligible households in the settlement with the desired cluster household size (15). Subsequently, we randomly selected a starting point on the line list and all subsequent households after addition of the sampling interval. Therefore, a sample of 15 households was randomly selected in each settlement providing a total of 1,800 households in 12 out of the 13 LGAs involved in the ORI (one LGA [Biu] was not surveyed due to insecurity).

#### *PCCS – Data Collection*

We collected data using Open Data Kit software running on android mobile phones. On completion of the household roster, only age-eligible respondents were present for interviewing. Information on the children receiving measles vaccination (i.e. children aged 9 to 71 months with SIA cards and recall) including vaccination coverage during the measles campaign were collected.

Design weights were calculated as the product of inverse probabilities of selection in the first and second stages. Data collection was conducted between 7<sup>th</sup> and 19<sup>th</sup> of July 2019.

### *PCCS – Data Cleaning and Analysis*

We used the SIA module of Vaccination Coverage Quality Indicators software running on Stata version 15 (StataCorp. 2017) for data cleaning and analysis. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC) [18]. Results are based on the weighted data to account for the survey sampling design and non-response. Wilson's 95% confidence intervals and upper and lower confidence bounds have been computed.

## **Results**

### *Description of the outbreak and the response*

The number of reported cases of measles per week of onset began to increase in week 2 and remained elevated until week 9, 2019. Of the total 15,237 reported cases from Borno, 2,002 suspected cases were line-listed and investigated from 17 LGAs as of March 2019 (epidemiologic week 9), and 737 were confirmed (103 IgM positive by laboratory testing and 634 epi-linked) (**Figure 1** and **Table 1**). Of the investigated cases, 1,348 (67.3%) were between 9 and 59 months of age; 145 (7.2%) were infants aged 9 – 11 months.

Among the 737 confirmed cases (all age groups), 64 cases (9%) stated (by recall and vaccination card) being vaccinated with at least 1 dose of measles-containing vaccine. Eight cases from 9 – 11 months were vaccinated for measles (**Table 1**). The proportion of unvaccinated cases was higher among the 12 – 23 months (134 cases) and 24 – 35 months (106 cases). The geographic distribution of investigated/line listed cases are shown in **Figure 2**. The number of reported cases were greater in MMC (attack rate per 100,000: 50.70), followed by Bama (attack rate per 100,000: 331.43), Konduga (attack rate per 100,000: 28.14) and Jere (attack rate per 100,000: 14.19).

The first phase of the ORI in MMC was conducted in epidemiologic week 11 and during week 20 in the remaining LGAs. The number of children vaccinated with measles vaccine was 437,515 (administrative coverage: 94%) during phase 1, and 800,666 (administrative coverage 95%) children during phase 2.

### *Vaccine effectiveness*

A total of 468 cases were confirmed from the age group 9 to 71 months and among them, 47 were vaccinated. At 9 – 11 months of age, 12 – 23 months and 24 – 35 months, the VE was 87.3% (95%CI: 71.0 – 95.2), 96.2% (95%CI: 92.6 – 98.3) and 97.3% (95%CI: 95.1 – 98.7) respectively (**Table 2**). The highest VE was nearly 100% for the age group 60 – 71 months (99.5%; 95%CI: 98.3 – 99.9). The overall VE for MCV was 98.4 (95%CI: 97.8 – 98.8).

### *Sensitivity Analysis*

When estimating the VE by final classification of cases, 44 epi-linked cases were accounted as receiving one or two doses of MCV and 3 lab-confirmed cases were found receiving one dose. The VE was then estimated at 68.3% (95%CI: -509 – 99.5) for lab-confirmed cases and 88.5% (95%CI: 72.1 – 96.1) for epi-linked cases of children 9 to 11 months. The VE for lab-confirmed cases was low as the PCV (only 1 vaccinated cases out of the 3 lab-confirmed cases; PCV: 0.33, 95%CI: 0.01 – 0.91) was high.

When at 12 to 23 months, the VE estimate was 95.9% (95%CI: 71.5 – 99.9) for lab-confirmed cases and 96.3% (95%CI: 92.4 – 98.4) for epi-linked cases; The original VE was estimated at 96.2% (95%CI: 92.6 – 98.3) for this age group. No significant differences were observed in the VE estimates of the two scenarios (lab-confirmed vs epi-linked) when compared to the original estimates; with the exception of the 9 months to 11 months for lab-confirmed (**Table 3**).

### *Post campaign coverage survey*

The proportion of individuals who received measles vaccination during the ORI by source of information on vaccination status and age group are shown in **Table 4**. The aggregated weighted coverage is 85.7% (95%CI: 79.6 – 90.1). Children under 9 months

and 24 to 35 months age group had the highest coverage at 100 and 92.8% respectively. While 80% of all respondents reported having received vaccination cards during the campaign, only 32.2% (95%CI: 25.0 – 40.3) had card evidence for their vaccination status. Fifty-three percent (53.5%) of individuals who were vaccinated had no card evidence for their vaccination.

## Discussion

Increased attacks in Borno State in December 2018 led to a massive population displacement. Subsequently, there were an increasing number of unvaccinated children who moved toward MMC and living in IDP camps in conditions favoring measles transmission. An ORI was essential for improving population immunity and interrupting the large measles outbreak in line with the global measles and rubella control and elimination goals [19].

The State has a history of outbreaks of measles in the last 5 years due to persistently low routine immunization coverage, and has been conducting measles campaigns almost every 2 years as a key strategy for reaching high-risk populations in security challenged/hard-to-reach areas. In November 2015, Borno responded to a measles outbreak targeting 1,255,100 children aged 6 to 59 months for vaccination with MCV. Only 66.7% (837,743 children) of the targeted children were vaccinated during the response. In early 2017, a mass measles vaccination campaign was implemented as part of outbreak preparedness in conflict-affected areas of Borno state. The campaign was implemented in 25 LGAs of the State. According to the PCCS concluded in February 2018, the proportion of children aged 9 months to 59 months who received measles vaccine during the 2017 campaign was 72.2% and, of all respondents, only 52.2% had received measles vaccines before the campaign [20].

During the 2019 ORI, a total of 1,238,181 children were vaccinated with MCV giving an administrative coverage of 98.75%. As administrative coverage reports may not always be accurate, a PCCS was conducted and has indicated an aggregated weighted coverage for the 12 LGAs included in the survey of 85.7%. The 95% coverage objective was not achieved due to the complexity in conducting a vaccination campaign in an emergency setting where insecurity, regular influx of new persons, population displacement, and hard-to-reach areas are extensive. In order to overcome these obstacles, collaboration with the military enabled the vaccination teams to immunize eligible children in security compromised areas. This strategy builds upon the Reaching Inaccessible Children strategy (RIC) conducted by the military and the Reaching Every Settlement (RES) strategy which uses some military support to reach areas that were partially or completely inaccessible to the vaccination teams. [17]. In recently accessed territories at the time of the ORI (i.e. camps and communities in Bama, Gwoza, Dikwa, Damboa, Ngala, Kukawa and Monguno LGAs), “hit and run” vaccination activities have been conducted with military escort to provide immunization and basic health care in the camps in these areas. Additionally, in hard-to-reach settlements, the polio eradication platform was used to reach underserved communities with measles vaccination [21].

Data on measles VE estimations in emergency settings in Nigeria and other countries are limited, and, where available, quite dated. During a measles outbreak in refugee camps in Mozambican refugee camps in Malawi, VE was estimated for children less than 5 years using the screening method. The findings of this investigation showed a VE of more than 90% [22]. A two-stage cluster survey of 563 children in famine emergencies in Ethiopia found a low VE of 66.9% in children 9–36 months old. The authors suggested problems with the cold chain or vaccine administration [7]. We have obtained a high estimate of MCV VE among all age groups during ORI in Borno state Nigeria. VE ranged from 87.3% (95%CI: 71.0, 95.2) to 99.5% (95%CI: 98.3 – 99.9) for children from 9 to 71 months. Measles VE at 9–11 months and in those greater than 12 months of age is expected to range between 84% and 92.5% [5].

Despite the limited storage capacity and poor immunization infrastructures at the lower level, efforts were made to ensure adequate cold chain and vaccine handling. Upon receipt of the MCV in-country, the vaccines were prepositioned in the Zonal cold store in Bauchi State (452 km driving distance to MMC). The vaccines and devices were distributed from the Zonal to the State store 2 weeks before the commencement of the ORI. The State distributed bundled vaccines to the LGA stores ahead of the campaign using cold boxes. Fast-cold chain was used to comply with the vaccine distribution process up to the communities and service delivery points.

This study is subject to some limitations. First, the result of the PCCS survey cannot be generalized to all children in the eligible age group in Borno state. The PCCS coverage results do not include coverage for children in the 14 LGAs that were not included in

the survey since they were not part of the ORI and the additional LGA (Biu) dropped from the survey due to insecurity. The survey teams did not visit IDP camps and in addition, as a consequence of the ongoing insecurity, there has been constant displacement and migration of populations within and out of Borno state. The number of children eligible for vaccination at any settlement in Borno state is constantly changing and it is difficult to track movements and how the movements may affect the proportion of vaccinated and unvaccinated children. Limiting the analysis to non-IDP cases may under-estimate the PPV of the case population. Secondly, the vaccination status of children in the inaccessible wards could not be estimated. The final limitation of the PCCS is (due to security challenges) the lag time of 4 months and 2 months between completion of the two phases of the campaign and timing of the survey. This may have influenced survey results as a consequence of recall bias. Only 32% of all interviewed individuals produced their vaccination cards, and 20% did not receive cards or could not recall whether they received vaccination cards. Considering multiple antigens delivered in the RI schedule and periodic ORI and preventive supplementary immunization activities, it is difficult for parents to accurately recall all doses of all antigens received by their child in the absence of widespread retention of vaccination cards. However, as demonstrated by previous immunization surveys conducted in Nigeria, using cards alone actually underestimates coverage, if not all doses are recorded [23].

In addition to the above mentioned limitations, there are some potential biases in all observational VE studies including the screening method. [24]. Specifically, bias related with misclassification and definition of cases, and recording of vaccination status. In our study, these biases were minimized by using the WHO standard case definition for measles, and the cases that were investigated and line-listed by the surveillance officer (i.e. DSNO).

## Conclusions

Our findings suggest that decreased VE is unlikely to explain the recurrence of measles outbreaks in Borno State. Insecurity resulting in lack of health and immunization services, frequent population displacements and clustering of susceptible children in IDPs are more likely contributors to measles morbidity and mortality in the State. [25]. Despite the estimated VE from the ORI activities, sub-optimal RI coverage is insufficient to maintain population immunity and prevent the accumulation of susceptible children that allow outbreaks to occur.

This analysis provides important insight for future vaccination in emergency and humanitarian settings in Nigeria and elsewhere. Data on the target age range for vaccination campaigns and strategies for measles control in response to an outbreak of measles in complex emergencies are available [26–28]. Adequate VE can be obtained with appropriate cold chain capacity when conducting ORI in situations where insecurity may challenge vaccine conservation. The integration with other health strategies (i.e. polio platform) and the engagement of security personnel increased the number of communities that could be accessed and reduced the time spent in these areas by the vaccination team. As measles has been one of the major causes of child deaths in complex emergencies, regular assessment of local measles epidemiology and population immunity status is recommended to determine the risk of an outbreak [6,27].

## Abbreviations

DSNOs: Disease Surveillance and Notification Officers; FCT: Federal Capital Territory; IDPs: Internally Displaced Persons; Ig: Immunoglobulin; LGAs: local government areas; MCV: measles-containing vaccine; MMC: Maiduguri Metropolitan Council; NPHCDA: National Primary Health Care Development Agency; PCCS: post-campaign coverage survey; PCV: proportion of cases vaccinated; PPV: proportion of the population vaccinated; RES: Reaching Every Settlement; RIC: Reaching Inaccessible Children strategy; RRT: Rapid Response Team; SIA: supplemental immunization activities; VE: Vaccine Effectiveness; WHO: World Health Organization

## Declarations

### Ethics approval and consent to participate

The analyses for this work was built on secondary data, which does not elicit consultation of an ethics committee and consent to participate, is not required. In coverage surveys written consent is not required. However, verbal consent to participate was

obtained from each participant during the interview.

### Consent for publication

Not applicable.

### Availability of data and material

Some of the data sets used in this paper are publicly available via the sources referenced in the manuscript (i.e. Nigeria Demographic and Health Survey 2018). Others are confidential (i.e. measles case-based with patient details) and the authors do not have the permission to share these data.

### Competing interests

The authors declare that they have no competing interests.

### Funding

No specific funding was provided for this study.

### Authors' contributions

AEJ, JW, SH, DK, IV, ES and EH conceived of the study idea, contributed to the study design and literature search. AEJ, JW, CI, AM, BD and DK contributed to data collection, preparation of figures and tables. AEJ, RL, DK, IV, ES, BM, SH, EH, JO, SM and FB performed the analysis. All contributed to interpretation and writing.

### Acknowledgements

Special gratitude goes to NPHCDA, Borno State Primary Health Care Development Agency (SPHCDA), Borno LGA Health Teams, WHO Borno State Office and field staffs. We gratefully acknowledge the vaccination team members and the community leaders for their contributions and the successful implementation of the ORI which this report is based. We would also like to thank Dr. Annick Eudes Jean Baptiste for her valuable technical assistance on the geographic information system – GIS data and maps development.

## References

1. World Health Organization (WHO). Progress towards regional measles elimination – worldwide, 2000–2017. *Weekly Epidemiol rec.* 48, 2018, 93, 649–660. 2018.
2. World Health Organization (WHO). Progress towards regional measles elimination – worldwide, 2000–2018. *Weekly Epidemiol rec.* 49, 2019, 94, 581–600 [Internet]. Available from: <http://www.who.int/emergencies/diseases/mrtbd/measles>
3. Ophori EA, Tula MY, Azih A V, Okojie R, Ikpo PE. Current Trends of Immunization in Nigeria: Prospect and Challenges. *Trop Med Health.* **2014**; .
4. STATISTICS NBO, SOC. The Federal Republic of Nigeria Nigeria Demographic and Health Survey 2018 National Population Commission Abuja, Nigeria [Internet]. 2019. Available from: [www.dhsprogram.com](http://www.dhsprogram.com).
5. WHO. Measles vaccines: WHO position paper, April 2017 - Recommendations. *Vaccine.* **2017**; .
6. Grais RF, Strebel P, Mala P, Watson J, Nandy R, Gayer M. Measles vaccination in humanitarian emergencies: A review of recent practice. *Confl Health* [Internet]. BioMed Central Ltd; **2011**; 5(1):21. Available from: <http://www.conflictandhealth.com/content/5/1/21>
7. Talley L, Salama P. Short report: Assessing field vaccine efficacy for measles in famine-affected rural ethiopia. *Am J Trop Med Hyg.* **2003**; 68(5):545–546.
8. World Health Organization. Response to measles outbreaks in measles mortality reduction settings. *World Heal Organ* [Internet]. **2009**; WHO/IVB/09:45. Available from: [http://whqlibdoc.who.int/hq/2009/WHO\\_IVB\\_09.03\\_eng.pdf](http://whqlibdoc.who.int/hq/2009/WHO_IVB_09.03_eng.pdf)

9. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. *Bull World Health Organ.* **1985**; .
10. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: A review of published literature. *J Infect Dis.* **2011**; 204(SUPPL. 1).
11. STATISTICS NBO, SOC. SOCIAL STATISTICS IN NIGERIA Federal Republic of Nigeria. 2009.
12. OCHA. Humanitarian Snapshot: New Displacement in Borno State since 1 Nov 2018. 2019.
13. Masresha BG, Braka F, Onwu NU, et al. Progress Towards Measles Elimination in Nigeria: 2012 – 2016. *J Immunol Sci Res Artic Immun African Reg Prog Towar Measles Elimin* [Internet]. **2018**; (2018):2012–2016. Available from: <http://www.immunologyresearchjournal.com/articles/progress-towards-measles-elimination-in-nigeria-2012-2016.pdf>
14. World Health Organization. WHO | Measles and Rubella Surveillance Data [Internet]. [cited 2020 Sep 21]. Available from: [https://www.who.int/immunization/monitoring\\_surveillance/burden/vpd/surveillance\\_type/active/measles\\_monthlydata/en/](https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/)
15. WHO. Measles - Vaccine Preventable Diseases. *WHO/Vaccine Biol.* 2018. p. 1–30.
16. WHO Regional Office for Africa. African Regional Guideline for Measles and Rubella Surveillance. **2015**; Revised Ve(April 2015):1–82. Available from: [http://www.afro.who.int/sites/default/files/2017-06/who-african-regional-measles-and-rubella-surveillance-guidelines\\_updated-draft-version-april-2015\\_1.pdf](http://www.afro.who.int/sites/default/files/2017-06/who-african-regional-measles-and-rubella-surveillance-guidelines_updated-draft-version-april-2015_1.pdf)
17. Nkwogu L, Shuaib F, Braka F, et al. Impact of engaging security personnel on access and polio immunization outcomes in security-inaccessible areas in Borno state, Nigeria. *BMC Public Health.* **2018**; 18(Suppl 4).
18. Biostat Global Consulting. VCQI Resources [Internet]. [cited 2020 Jan 4]. Available from: [http://www.biostatglobal.com/VCQI\\_resources.html](http://www.biostatglobal.com/VCQI_resources.html)
19. World Health Organization. GLOBAL MEASLES AND RUBELLA: Strategic Plan 2012-2020 [Internet]. *World Heal. Organ.* 2012. Available from: [http://www.who.int/immunization/documents/control/ISBN\\_978\\_92\\_4\\_150339\\_6/en/](http://www.who.int/immunization/documents/control/ISBN_978_92_4_150339_6/en/)
20. NPHCDA N. Post Measles Campaign Coverage Survey Main Survey Report. 2018.
21. Bawa S, McNab C, Nkwogu L, et al. Using the polio programme to deliver primary health care in Nigeria: Implementation research. *Bull World Health Organ.* **2019**; 97(1):24–32.
22. Yamaguchi S, Dunga A, Broadhead RL, Brabin BJ. Epidemiology of measles in Blantyre, Malawi: analyses of passive surveillance data from 1996 to 1998. *Epidemiol Infect.* Cambridge University Press; **2002**; 129:361–369.
23. World Health Organization (WHO). Meeting Report Meeting to share lessons learnt from the roll-out of the 2015 WHO Vaccination Coverage Cluster Survey Reference Manual and to set an operational research agenda around vaccination coverage surveys [Internet]. 2017. Available from: <http://bit.ly/WHO-vax-survey-mtg>
24. Torvaldsen S, McIntyre PB. Observational methods in epidemiologic assessment of vaccine effectiveness. **2002**; 26(3):451–457.
25. Boven M Van, Kretzschmar M, Wallinga J, O'Neill PD, Wichmann O, Hahné S. Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. *J R Soc Interface.* **2010**; 7(52):1537–1544.
26. World Health Organization, UNICEF. WHO/UNICEF Joint Statement on reducing measles mortality in emergencies. **2004**; :1–4. Available from: [http://www.unicef.org/publications/index\\_4444.html](http://www.unicef.org/publications/index_4444.html)
27. SAGE Working Group on vaccination in humanitarian emergencies. Vaccination in Humanitarian Emergencies: Literature review and case studies. **2011**; (September):1–21.
28. Kouadio IK, Kamigaki T, Oshitani H. Measles outbreaks in displaced populations: A review of transmission, morbidity and mortality associated factors. *BMC Int Health Hum Rights.* **2010**; 10(1).

## Tables

**Table 1. Number and proportion (%) of investigated reported cases by age-group and vaccination status. Borno, December 2018 – March, 2019**

| Age group      | Cases reported |             | Confirmed cases* |             |              |             |                     |             |            |             |
|----------------|----------------|-------------|------------------|-------------|--------------|-------------|---------------------|-------------|------------|-------------|
|                | No.            | %           | All              |             | Unvaccinated |             | Unknown vaccination |             | Vaccinated |             |
|                | No.            | %           | No.              | %           | No.          | %           | No.                 | %           | No.        | %           |
| < 9 months     | 169            | 8.4%        | 61               | 8.3%        | 61           | 9.3%        | 0                   | 0.0%        | 0          | 0.0%        |
| 9 - 11 months  | 145            | 7.2%        | 49               | 6.6%        | 38           | 5.8%        | 3                   | 15.0%       | 8          | 12.5%       |
| 12 - 23 months | 429            | 21.4%       | 148              | 20.1%       | 134          | 20.5%       | 3                   | 15.0%       | 11         | 17.2%       |
| 24 - 35 months | 355            | 17.7%       | 127              | 17.2%       | 106          | 16.2%       | 2                   | 10.0%       | 19         | 29.7%       |
| 36 - 47 months | 251            | 12.5%       | 98               | 13.3%       | 87           | 13.3%       | 5                   | 25.0%       | 6          | 9.4%        |
| 48 - 59 months | 168            | 8.4%        | 65               | 8.8%        | 51           | 7.8%        | 3                   | 15.0%       | 11         | 17.2%       |
| 60 - 71 months | 124            | 6.2%        | 54               | 7.3%        | 50           | 7.7%        | 0                   | 0.0%        | 4          | 6.3%        |
| > 71 months    | 361            | 18.0%       | 135              | 18.3%       | 126          | 19.3%       | 4                   | 20.0%       | 5          | 7.8%        |
| <b>Total</b>   | <b>2002</b>    | <b>100%</b> | <b>737</b>       | <b>100%</b> | <b>653</b>   | <b>100%</b> | <b>20</b>           | <b>100%</b> | <b>64</b>  | <b>100%</b> |

Source: Outbreak investigation report and Measles Line-list.

**Table 2. Age-specific vaccine effectiveness of confirmed measles cases.  
Borno, December 2018 - March, 2019**

| Age Group      | Vaccinated cases | Confirmed* cases | PCV (95% CI)              | PPV         | VE % (95% CI)             |
|----------------|------------------|------------------|---------------------------|-------------|---------------------------|
| < 9 months**   | 1                | 49               | 0.02 (0.00 - 0.11)        | 0.00        | -                         |
| 9 - 11 months  | 7                | 42               | 0.17 (0.07 - 0.31)        | 0.61        | 87.3 (71.0 - 95.2)        |
| 12 - 23 months | 9                | 118              | 0.08 (0.04 - 0.14)        | 0.69        | 96.2 (92.6 - 98.3)        |
| 24 - 35 months | 12               | 97               | 0.12 (0.07 - 0.21)        | 0.84        | 97.3 (95.1 - 98.7)        |
| 36 - 47 months | 5                | 75               | 0.07 (0.02 - 0.15)        | 0.84        | 98.6 (96.7 - 99.6)        |
| 48 - 59 months | 10               | 49               | 0.20 (0.10 - 0.34)        | 0.70        | 89.2 (77.9 - 95.2)        |
| 60 - 71 months | 3                | 38               | 0.08 (0.02 - 0.21)        | 0.94        | 99.5 (98.3 - 99.9)        |
| <b>Overall</b> | <b>47</b>        | <b>468</b>       | <b>0.10 (0.07 - 0.13)</b> | <b>0.88</b> | <b>98.4 (97.8 - 98.8)</b> |

PCV = Proportion of cases vaccinated; PPV = Proportion of the population vaccinated based on 2018 PCCS report;

VE = Vaccine effectiveness; CI = Confidence Interval.

\* Cases reported from IDP camps were excluded from the VE estimation as the PCCS did not capture coverage from IDP camps.

\*\* The < 9 month old infants were not scheduled for measles vaccination and were excluded from the VE estimation.

**Table 3. Sensitivity analyses of lab-confirmed and epi-linked cases, and age-specific vaccine effectiveness.  
Borno, December 2018 - March, 2019**

| Original VE    |                           | Sensitivity analyses       |                  |                           |                           |                         |                  |                           |                           |
|----------------|---------------------------|----------------------------|------------------|---------------------------|---------------------------|-------------------------|------------------|---------------------------|---------------------------|
| Age Group      | VE% (95% CI)              | VE for lab-confirmed cases |                  |                           |                           | VE for epi-linked cases |                  |                           |                           |
|                |                           | Vaccinated cases           | Confirmed* cases | PCV (95% CI)              | VE% (95% CI)              | Vaccinated cases        | Confirmed* cases | PCV (95% CI)              | VE% (95% CI)              |
| < 9 mo**       | -                         | 0                          | 2                | 0.00 (0.00 - 0.84)        | -                         | 1                       | 47               | 0.02 (0.00 - 0.11)        | -                         |
| 9 - 11 mo      | 87.3 (71.0 - 95.2)        | 1                          | 3                | 0.33 (0.01 - 0.91)        | 68.3 (-509 - 99.5)        | 6                       | 39               | 0.15 (0.06 - 0.31)        | 88.5 (72.1 - 96.1)        |
| 12 - 23 mo     | 96.2 (92.6 - 98.3)        | 1                          | 12               | 0.08 (0.00 - 0.38)        | 95.9 (71.5 - 99.9)        | 8                       | 106              | 0.08 (0.03 - 0.14)        | 96.3 (92.4 - 98.4)        |
| 24 - 35 mo     | 97.3 (95.1 - 98.7)        | 0                          | 11               | 0.00 (0.00 - 0.28)        | 100.0 (92.4 - 100.0)      | 12                      | 86               | 0.14 (0.07 - 0.23)        | 96.9 (94.3 - 98.5)        |
| 36 - 47 mo     | 98.6 (96.7 - 99.6)        | 0                          | 7                | 0.00 (0.00 - 0.41)        | 100.0 (86.8 - 100.0)      | 5                       | 68               | 0.07 (0.02 - 0.16)        | 98.5 (96.3 - 99.5)        |
| 48 - 59 mo     | 89.2 (77.9 - 95.2)        | 1                          | 8                | 0.13 (0.00 - 0.51)        | 94.0 (53.0 - 99.9)        | 9                       | 41               | 0.22 (0.11 - 0.38)        | 88.1 (74.5 - 95.0)        |
| 60 - 71 mo     | 99.5 (98.3 - 99.9)        | 0                          | 7                | 0.00 (0.00 - 0.41)        | 100.0 (95.6 - 100.0)      | 3                       | 31               | 0.10 (0.02 - 0.26)        | 99.3 (97.8 - 99.9)        |
| <b>Overall</b> | <b>98.4 (97.8 - 98.8)</b> | <b>3</b>                   | <b>50</b>        | <b>0.06 (0.01 - 0.17)</b> | <b>99.1 (97.2 - 99.8)</b> | <b>44</b>               | <b>418</b>       | <b>0.11 (0.08 - 0.14)</b> | <b>98.3 (97.7 - 98.8)</b> |

Mo = month; PCV = Proportion of cases vaccinated; PPV = Proportion of the population vaccinated based on 2018 PCCS report; VE = Vaccine effectiveness; CI = Confidence Interval.

\* Cases reported from IDP camps were excluded from the VE estimation as the PCCS did not capture coverage from IDP camps.

\*\* The < 9 months' infants were not scheduled for measles vaccination and were excluded from the VE estimation.

**Table 4. Post measles campaign survey by card and by recall. Borno\*, July 2019**


|                     | Vaccinated by recall |                      | Vaccinated by card** |                      | Vaccinated by card or recall |                      | N            | Weight       |
|---------------------|----------------------|----------------------|----------------------|----------------------|------------------------------|----------------------|--------------|--------------|
|                     | %                    | CI                   | %                    | CI                   | %                            | CI                   |              |              |
| <b>Borno</b>        | <b>53.5</b>          | <b>(45.4 - 61.4)</b> | <b>32.2</b>          | <b>(25.0 - 40.3)</b> | <b>85.7</b>                  | <b>(79.6 - 90.1)</b> | <b>1,440</b> | <b>1,440</b> |
| <b>Age category</b> |                      |                      |                      |                      |                              |                      |              |              |
| < 9 months          | 28.8                 | (4.3 - 78.4)         | 71.2                 | (21.6 - 95.7)        | 100.0                        | (20.7 - 100)         | 6            | 2            |
| 9 - 11 months       | 52.6                 | (25.2 - 78.6)        | 33.5                 | (13.4 - 62.2)        | 86.2                         | (61.9 - 96.0)        | 31           | 15           |
| 12 - 23 months      | 50.3                 | (36.0 - 64.5)        | 28.6                 | (18.7 - 41.1)        | 78.9                         | (58.5 - 90.9)        | 283          | 308          |
| 24 - 35 months      | 54.9                 | (43.8 - 65.6)        | 37.8                 | (27.5 - 49.5)        | 92.8                         | (87.2 - 96.0)        | 368          | 333          |
| 36 - 47 months      | 43.4                 | (33.0 - 54.4)        | 42.9                 | (31.7 - 54.8)        | 86.2                         | (77.6 - 91.9)        | 376          | 387          |
| 48 - 59 months      | 61.8                 | (50.8 - 71.7)        | 22.4                 | (14.6 - 32.7)        | 84.2                         | (73.8 - 91.0)        | 308          | 296          |
| 60 - 71 months      | 66.7                 | (28.9 - 90.8)        | 11.5                 | (3.2 - 34.2)         | 78.2                         | (30.1 - 96.8)        | 42           | 28           |
| > 71 months         | 75.7                 | (37.4 - 94.2)        | 11.7                 | (1.9 - 46.8)         | 87.3                         | (56.7 - 97.3)        | 26           | 71           |

\* Thirteen (13) LGAs out of the 27 LGAs of Borno States were involved in the ORI. Fifteen (15) of the 27 LGAs of Borno State were not included in the survey.

\*\*80% of all respondents reported having received vaccination cards during the campaign.


CI = Confidence Interval; N = Number interviewed.

## Figures



**Figure 1**

Confirmed cases of measles by week of rash onset, Borno State, Nigeria, December 2018 – March, 2019. As of epidemiologic week 9, a total of 2,002 cases were investigated and line-listed. Among the investigated cases, 737 were confirmed for measles.



**Figure 2**

Reported measles cases. Borno state, Nigeria, December 2018 – March, 2019. Measles cases = Cases investigated and line-listed; Source: Borno State measles line-list. The number of measles cases were greater in Maiduguri (attack rate per 100,000: 50.70), followed by Bama (attack rate per 100,000: 331.43), Konduga (attack rate per 100,000: 28.14) and Jere (attack rate per 100,000: 14.19). Challenges around accessibility to various communities to implement and provide health services remain a barrier in

Borno State. At the time of the outbreak response immunization, two LGAs (i.e. Abadam and Marte) were totally inaccessible and, only four LGAs (out of the 27) and the state capital (Maiduguri) were fully accessible. The remaining LGAs were partially accessible.